Pfizer has announced the global withdrawal of its sickle cell disease treatment, Oxbryta (voxelotor), which was priced at approximately $125,000 per year. The decision follows a review of clinical data that revealed significant safety concerns, including an increased risk of complications and patient fatalities. Oxbryta, initially priced at $10,417 per month, was hailed as a …
About admin
